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Abstract:  
Thermal ablation processes hold the promise of less invasive cancer management. But 
broader acceptance of cancer ablation processes is hindered by controversial issues and 
concerns due to the lack of effective assessment of the ablation margin during surgery. We 
developed heat-sensitive microbubbles for ablation margin assessment during a cancer 
ablation surgery. The heat-sensitive microbubbles, which comprise a core of liquid 
perfluorocarbons (PFC) within a biodegradable poly lactic-co-glycolic acid (PLGA) shell, 
were fabricated using an emulsion evaporation method. Optical microscopic imaging showed 
that, at the boiling point of PFC (55ºC), the microbubbles expanded from 1 µm to 20 µm due 
to PFC evaporation. Additionally, the microbubbles were embedded in a tissue simulating 
phantom made of agar-agar gel for ultrasound imaging. At room temperature, the 
microbubbles were not detected by the ultrasound. After being evenly heated to 55 ºC for 10 
minutes, the microbubbles were clearly visualized by the ultrasound. These results 
demonstrate that the heat sensitive microbubbles can be potentially utilized as an ultrasound 
contrast agent for thermal ablation margin assessment. Successful implementation of these 
heat-sensitive microbubbles may enhance the accuracy for cancer ablation and revolutionize 
the clinical practice of cancer management. 
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1. Introduction 
Thermal ablation is a minimally-invasive technique for cancer treatment that has received 
increasing interests in recent years. As an alternative to traditional surgical intervention for 
cancer treatment, thermal ablation uses heat to destroy cancerous tissue and the surrounding 
margin. Several thermal ablation techniques have been implemented clinically, including 
radiofrequency (RF) ablation[1], laser ablation[2], High Intensity Focused Ultrasound (HIFU) 
ablation [3], and microwave ablation[4]. Thermal ablation holds the promise of less invasive 
cancer management with outpatient treatments, minimal trauma, minimal side effects and 
short recovery time[5, 6]. However, broader acceptance of cancer ablation processes is 
hindered by controversial issues and concerns related with clinical safety, efficacy, and 
long-term local recurrence[7, 8]. These concerns are due to the lack of effective assessment 
of the ablation margin during the thermal ablation therapy[5, 6, 8]. 
Thermal ablation destroys the tumor tissue by localized deposition of thermal energy that 
causes protein denaturation and coagulation necrosis. At the typical ablation temperature 
ranging from 50ºC to 100ºC, irreversible tissue damage occurs after 2 minutes of heating [5]. 
The ablation margin (i.e., the region of effective tissue destruction) can be defined by the 
50–54ºC contour and a ‘lethal thermal dose’,  which can be determined by both tissue 
temperature and thermal exposure time[5]. The lethal thermal dose varies with tissue types, 
with a typical value of 240–540 min at 43ºC (t43>240–540 min). For complete destruction of 
tumor, the tumor plus a 1 cm margin of surrounding normal tissue should be ablated[6]. 
Incomplete ablation may lead to local recurrence which is the re-growing of residual 
cancerous cells into tumor. In this regard, it is important to monitor the thermal dose and the 
ablation margin during a thermal ablation therapy.  
Existing methods for the assessment of ablation-induced tissue damage include MR 
thermometry, MR elastography, and visible light spectroscopy [9-11]. These methods do not 
provide reliable assessment of ablation margins. For example, MR thermometry records the 
transient tissue temperature map [3, 11-15] and the necrotic margin is estimated based on the 
Arrhenius model that counts both amplitude and duration of heating [12]. However, 
disagreement was observed between MR thermal dose maps and actual lesion sizes [16], 
possibly due to the accumulative errors in numerical models and temperature measurements. 
Besides, MR thermometry has the following limitations: (1) it is susceptible to motion artifact 
and tissue swelling[14, 15, 17]; (2) it has low sensitivity in fat tissue[18]; (3) it requires 
custom design of the thermal therapy system; (4) it’s size is large and cost is high. 
To overcome the above limitations, we are currently developing heat-sensitive microbubbles 
for real-time, motion insensitive, intraoperative imaging and assessment of cancer ablation 
margin. Heat-sensitive microbubbles conjugated with tumor specific biomarkers will target 
the tumor receptors and deposit at the tumor site after intravenous administration. During 
thermal ablation, microbubbles will expand at the lethal thermal dose to significantly enhance 
ultrasound contrast, enabling direct visualization of ablation margin using clinical ultrasound.  
This paper summarizes our current work on heat-sensitive microbubbles. The heat-induced 
microbubble expansion has been visualized by optical microscopic imaging. The feasibility 
of using heat-sensitive microbubbles for cancer ablation margin assessment has been 
demonstrated using tissue-simulating phantom and ultrasound imaging.  
 
2. Materials and methods 
2.1 Materials 
Poly lactide-co-glycolide (PLGA) was obtained from Boehringer Ingelheim (Ingelheim, 
Germany). Sodium cholate was purchased from Sigma-Aldrich Chemical Co. (St. Louis, 
MO). Methylene chloride (CH2Cl2) was provided from Fishers Scientific (Newton, NJ). 
1,1,1,2,3,4,4,5,5,5-Decafluoropentane was purchased from Fluka (St. Louis, MO). Since 
1,1,1,2,3,4,4,5,5,5-Decafluoropentane is one type of perfluorocarbons (PFC) compounds, it 
will be denoted as PFC in the following text for convenience. Ultrapure deionized water was 
generated by NANOpure Infinity water purification system (Barnstead International, 
Dubuque, IA).  
 
2.2 Fabrication of PFC encapsulated PLGA microbubbles 
PFC encapsulated PLGA microbubbles were fabricated by a modified emulsion evaporation 
method [19]. 25mg PLGA was dissolved in 2mL methylene chloride (CH
2
Cl
2
). Then 1mL 
PFC was added into the PLGA solution. The solution was then mixed into to 20mL 1.5 w/v% 
sodium cholate which acted as a surfactant. The final mixture was emulsified using a model 
17105 Omni Mixer homogenizer (Omini International, Waterbury, CT) at 20,000 rpm for 2 
minutes. After that, the emulsion was stirred by a magnetic bar for 3 hours for evaporation of 
CH
2
Cl
2
. Finally, the mixture was centrifuged by Centrifuge 5810R (Eppendorf, Hamburg, 
Germany) at 300 rpm for 5 minutes. After centrifugation, the supernatant was discarded, and 
the microbubble precipitate was saved and re-dispersed by the deionized water. The process 
of centrifugation and re-dispersing was repeated for three times. The microbubbles were then 
harvested and stored in deionized water for further use.  
 
2.3 Optical imaging and size distribution of microbubbles 
A Nikon TMS-F inverted optical microscope (Melville, NY) was used to visualize and 
monitor the heat-induced expansion of the PFC encapsulated PLGA microbubbles. A drop of 
microbubbles dispersed in water was put on the bottom of a cell culture dish and covered by a 
cover slip. It was made sure that no air bubble was under the cover slip. The surrounding of 
the cover slip was gently sealed by tape to prevent any leaking of the microbubble solution. 
The dish was then fixed to the right position under the microscope and images of 
microbubbles before expansion were recorded. After that, 55ºC water was filled into the dish 
and circulated between the dish and an ISOTEMP 215 water bath (Fisher Scientific) using a 
water pump (Cole-Parmer Instrument Inc, Chicago, IL). The microscopic image of heated 
microbubbles was recorded. Size distribution of the microbubbles before and after heating 
was calculated using image processing and analysis software ImageTool (UTHSCSA, version 
3.0). 
 
2.3 Tissue-simulating phantom and ultrasound imaging 
Heat-induced expansion of PFC encapsulated PLGA microbubbles was validated using tissue 
simulating phantom and ultrasound. The phantom was made by agar-agar gel (Barry Farm, 
Wapakoneta, OH) with a gelling temperature of 32ºC and melting temperature of 65ºC. 0.1g 
agar-agar gel powder was fully dissolved in 10mL 70ºC water in a 10mL beaker. As the 
temperature of agar-agar gel dropped to 37ºC, 150µL microbubble suspension (0.5mg/mL) 
was added to the gel and fully mixed by a glass stir bar. The mixture was then put inside a 
refrigerator for complete gelling. After that, the phantom was heated at 55ºC for 10 minutes 
inside a water bath. Ultrasound images were recorded before and after heating using a 
Terason 2000 ultrasound probe (Teratech Corp., Burlington, MA). As comparison, a control 
phantom was made following the identical recipe except that microbubble suspension was not 
added. The control phantom was heated at the same condition as that of the sample phantom. 
Ultrasound images of the control phantom were recorded before and after heating.  
 
3. Results 
Optical microscopic images of PFC encapsulated PLGA microbubbles before and after 
heating are shown in Fig.1. Corresponding size distributions of the microbubbles are shown 
in Fig.2. The mean radius of the microbubbles before heating is 1.26±0.51µm. After being 
heated at 55ºC for 10 minutes, the microbubbles exploded and expanded to 20.76±10.44 µm 
due to the evaporation of PFC. It was observed that the explosion of each bubble was 
instantaneous, and the adjacent microbubbles expanded and merged to form larger 
microbubbles. The coalescence of microbubbles contributed to the bubble size of greater than 
20 µm in the size distribution plot (Figure 2). At the current stage of technology development, 
the exact thermal dose for microbubbles expansion was not measured due to the complex heat 
transfer. However, a mathematical model will be developed and validated for the estimation 
of the required thermal dose for microbubble expansion, as being further discussed in the 
later section.  
 
Figure 1. Microscopic image of PFC encapsulated PLGA microbubbles 
(a) Before being heated to 55ºC; (b) After being heated to 55ºC 
 
 
Figure 2. Size distribution of PFC encapsulated PLGA microbubbles 
The mean radius of the microbubbles before being heated is 1.26 µm with a standard deviation of 0.51 
µm. After being heated above 55ºC for 10 minutes, PFC inside the microbubbles evaporated and the 
bubbles expanded to 20.76 µm with a standard deviation of 10.44 µm. 
 
 
Figure3. Ultrasound image of heat-sensitive PFC encapsulated PLGA microbubbles 
inside agar-agar gel tissue-simulating phantom before and after being heated to 55ºC. 
 
Fig. 3 shows the ultrasound images before and after heating for the agar-agar gel 
tissue-simulating phantoms with and without heat-sensitive microbubbles respectively. At the 
room temperature (20ºC), microbubbles in the gel phantom could not be detected by the 
ultrasound, indicating that the liquid PFC encapsulated microbubbles could not introduce 
significant ultrasound contrast. After the phantom was heated at 55ºC for 10 minutes, a 
number of hyperechoic areas presented in the ultrasound image, indicating the expansion of 
the heat-sensitive microbubbles due to PFC evaporation. In comparison, the same heating 
condition applied to the control phantom (i.e., the phantom without heat-sensitive 
microbubbles) did not introduce significant change of ultrasound contrast, ruling out the 
possibility of air bubble formation due to heating. The hyperechoic areas on the top of the 
image are due to air bubbles existing in the ultrasound matching gel between the ultrasound 
probe and the phantom surface.  
 
4. Conclusions and future works 
We developed the heat-sensitive microbubbles for ablation margin assessment during a 
cancer ablation surgery. The heat-sensitive microbubbles, which comprise a core of liquid 
PFC within a biodegradable PLGA shell, were fabricated using an emulsion evaporation 
method. Optical microscopic imaging showed that, at the boiling point of PFC (55ºC), the 
microbubbles expanded from 1 µm to 20 µm due to PFC evaporation. Additionally, the 
microbubbles were embedded in a tissue simulating phantom made of agar-agar gel for 
ultrasound imaging. At room temperature, the microbubbles were not detected by the 
ultrasound. After being evenly heated to 55 ºC for 10 minutes, the microbubbles were clearly 
visualized by the ultrasound. These results demonstrate that the heat sensitive microbubbles 
can be potentially utilized as an ultrasound contrast agent for thermal ablation margin 
assessment.  
Future research work includes the validation of this heat-sensitive ultrasound contrast agent 
for ablation margin assessment in animal models. Heat-sensitive nanobubbles with the size 
around 100 nm will be fabricated and conjugated with cancer-specific antibodies, such as 
CC49 that targets TAG-72, a human glycoprotein complex over-expressed in many 
epithelial-derived cancers, including colorectal, pancreatic, breast, ovarian, and gastric 
cancers [20]. A mathematical model will be developed to quantify the mechanism of 
heat-induced bubble expansion and guide the design and fabrication of heat-sensitive 
nanobubbles for the designated thermal dose that matches the lethal thermal dose for 
effective cancer cell destruction and coagulative necrosis. Finally, the use of heat-sensitive 
nanobubbles for ablation margin assessment will be demonstrated using perfused tissue 
models and cancer xenograft mice. Clinical safety has been considered in order to facilitate 
the translation of this imaging technique from bench-top to bedside. Materials used for 
fabrication of heat-sensitive microbubbles, PFC and PLGA, are biocompatible and 
biodegradable materials either approved by Food and Drug Administration (FDA) or used in 
clinical applications. The heat-sensitive microbubbles described in this paper may 
revolutionize the clinical practice of minimally invasive cancer management by providing 
real-time intraoperative information about the tumor ablation margins.  
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